Hong Kong Stock Market Movement | Most pharmaceutical stocks rise. Gilead Sciences-B(01672) up over 6%. Kangfang Biotech(09926) up over 5%.

LootboxPhobia · 2026-02-20T10:24:20+00:00

SmartTelling Finance APP has learned that most pharmaceutical stocks are rising. As of the time of writing, GenScript Pharmaceuticals-B(01672) increased by 6.33%, trading at HKD 17.65; Innovent Biologics(09926) increased by 5.23%, trading at HKD 110.7; Junshi Biosciences(01877) increased by 4.39%, trading at HKD 21.88; BeiGene(06160) increased by 4.37%, trading at HKD 214.8; ReBio Bio-B(06938) increased by 4.08%, trading at HKD 74.On the news front, at the start of 2026, China's innovative drug licensing (BD) market continued its strong growth momentum. In just over half of the first quarter, the total transaction amount exceeded $33.28 billion, with the upfront payments surpassing the highest level of a single quarter in 2025. Kaiyuan Securities believes that the innovative drug sector has corrected for nearly two quarters. In the long term, many high-quality targets are significantly undervalued, and the current position suggests increasing exposure to the sector.

LootboxPhobia

2026-02-20 10:24:20

China Securities Journal APP has learned that most pharmaceutical stocks are rising. As of the time of writing, GenScript Biotech (01672) increased by 6.33%, trading at HKD 17.65; Akeso (09926) rose by 5.23%, trading at HKD 110.7; Junshi Biosciences (01877) increased by 4.39%, trading at HKD 21.88; BeiGene (06160) rose by 4.37%, trading at HKD 214.8; Revo Biologics (06938) increased by 4.08%, trading at HKD 74.

On the news front, at the start of 2026, China’s innovative drug licensing and business development (BD) market continued its strong growth momentum. In just over half of the first quarter, total transaction volume exceeded $33.28 billion, with upfront payments surpassing the highest quarterly level of 2025. Kaiyuan Securities believes that the innovative drug sector has corrected for nearly two quarters. In the long term, many high-quality targets are now valued at attractive levels. The current position suggests increasing sector allocation, focusing on confirmed offshore opportunities and high-growth or clinically promising segments with high probability of successful overseas expansion.

Additionally, Donghai Securities previously pointed out that in 2025, the innovative drug sector entered a period of accelerated profitability realization. Companies like NuoCheng Jianhua and Rongchang Biotech turned losses into profits, while San Sheng Guojian and Shanghai Yizhong significantly increased their earnings. Junshi Biosciences notably reduced losses. The core drivers are mainly rapid commercialization of products and BD collaborations. The impressive performance of the innovative drug sector fully validates the effectiveness of the domestic innovation drug business model. Under the support of medical insurance, the volume growth of core products has become the foundation for performance growth, and external collaborations such as BD have become important means to boost earnings.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes